Rationale for and role of thiazolidinediones in type 2 diabetes mellitus
- 1 September 2002
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 90 (5) , 34-41
- https://doi.org/10.1016/s0002-9149(02)02557-2
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Prevalence of the Metabolic Syndrome Among US AdultsJAMA, 2002
- ORAL THERAPIES FOR DIABETIC HYPERGLYCEMIAEndocrinology and Metabolism Clinics of North America, 2001
- The dysmetabolic syndromeJournal of Internal Medicine, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Cardiovascular Morbidity and Mortality Associated With the Metabolic SyndromeDiabetes Care, 2001
- Insulin Resistance and Its Treatment by ThiazolidinedionesRecent Progress in Hormone Research, 2001
- Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonistsJournal of Clinical Investigation, 2000
- Insulin resistance and cardiovascular diseaseJournal of Clinical Investigation, 2000
- Diabetes MellitusArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Type 2 Diabetes: An OverviewClinical Chemistry, 1999